Pathstone Holdings
CNTX icon

Pathstone Holdings’s Context Therapeutics CNTX Stock Holding History

Pathstone Holdings’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Hold
110,244
– – ﹤0.01% 1990
2025
Q4 		$162K Hold
110,244
– – ﹤0.01% 2133
2025
Q3 		$107K Buy
+110,244
New +$89.4K ﹤0.01% 2267

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pathstone Holdings's CNTX Position: Q1 2026 in Review

Pathstone Holdings held its Context Therapeutics (CNTX) position steady in Q1 2026 at 110,244 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Pathstone Holdings first reported a position in CNTX in Q3 2025 and has held it in 3 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Pathstone Holdings held 110,244 shares of Context Therapeutics worth $289K as of Q1 2026.
  • Pathstone Holdings left its Context Therapeutics share count unchanged in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q1 2026, its #1990 holding.
  • Pathstone Holdings first reported a position in Context Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.